Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
Omeros estimates over 20,000 occurrences per year for US and EU for HSCT-TMA. Omeros is likely to price OMS721 at $300,000+. Currently these patient require treatment of $3 MM+ each and 90% do not survive 30 days. The drug potentially saves lives and reduced hospital expenses even at this high price.

Plus OMS721 is also in PH 3 for Igan a kidney disease impacting about 200,000 patient per year in US. More in EU & Asia.

Plus OMS721 in in PH 3 for Ahus. A disease that Alexion sells Solaris at $500,000 per patient per year and rakes in over $2.5 BB for this indication.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.